Immunorizon
T-and NK-cell Engagers for Cancer Therapy
StartupImmunorizon is a Yavne-based startup in the Health Tech & Life Sciences sector, established in 2017. T-and NK-cell Engagers for Cancer Therapy. Key investors include M Ventures, ExploreBio. The company has 1-10 employees. Core technologies: Biologicals, Cells.
The company follows a B2B business model. Product stage: Clinical Trial. Immunorizon has been acquired.
- StageAcquired
- ProductClinical Trial
- ModelB2B
- Employees1-10
- HQYavne
- DistrictCenter District
- StatusAcquired
- Last RoundUndisclosed
- M Ventures
- ExploreBio
What does Immunorizon do?
Immunorizon is developing conditionally activated tumor-restricted T- and NK-cell engagers for cancer therapy. The company extends its pipeline and uses tri-specific constructs with additional tumor-associated antigens and diverse engagers with both T-cells and NK-cells.
What sector is Immunorizon in?
Immunorizon operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells.
Where is Immunorizon located?
Immunorizon is based in Yavne, Israel, Center District.